HEADER TRANSFERASE/TRANSFERASE INHIBITOR 23-MAY-12 4FBX TITLE COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT TITLE 2 CRYSTALLIZED IN THE PRESENCE OF A BISUBSTRATE INHIBITOR COMPND MOL_ID: 1; COMPND 2 MOLECULE: CASEIN KINASE II SUBUNIT ALPHA; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: CK II ALPHA; COMPND 5 EC: 2.7.11.1; COMPND 6 ENGINEERED: YES; COMPND 7 MOL_ID: 2; COMPND 8 MOLECULE: BISUBSTRATE INHIBITOR; COMPND 9 CHAIN: B; COMPND 10 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: CSNK2A1, CK2A1; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 8 MOL_ID: 2; SOURCE 9 SYNTHETIC: YES KEYWDS PROTEIN KINASE FOLD, PROTEIN PHOSPHORYLATION, BISUBSTRATE INHIBITOR, KEYWDS 2 TRANSFERASE-TRANSFERASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR E.ENKVIST,K.VIHT,N.BISCHOFF,J.VAHTER,S.SAAVER,G.RAIDARU,O.- AUTHOR 2 G.ISSINGER,K.NIEFIND,A.URI REVDAT 4 10-JUL-24 4FBX 1 COMPND FORMUL REVDAT 3 28-FEB-24 4FBX 1 REMARK REVDAT 2 31-OCT-12 4FBX 1 JRNL REVDAT 1 17-OCT-12 4FBX 0 JRNL AUTH E.ENKVIST,K.VIHT,N.BISCHOFF,J.VAHTER,S.SAAVER,G.RAIDARU, JRNL AUTH 2 O.G.ISSINGER,K.NIEFIND,A.URI JRNL TITL A SUBNANOMOLAR FLUORESCENT PROBE FOR PROTEIN KINASE CK2 JRNL TITL 2 INTERACTION STUDIES. JRNL REF ORG.BIOMOL.CHEM. V. 10 8645 2012 JRNL REFN ISSN 1477-0520 JRNL PMID 23032938 JRNL DOI 10.1039/C2OB26022K REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH I.ERMAKOVA,B.BOLDYREFF,O.G.ISSINGER,K.NIEFIND REMARK 1 TITL CRYSTAL STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN REMARK 1 TITL 2 PROTEIN KINASE CK2 CATALYTIC SUBUNIT. REMARK 1 REF J.MOL.BIOL. V. 330 925 2003 REMARK 1 REFN ISSN 0022-2836 REMARK 1 PMID 12860116 REMARK 1 REFERENCE 2 REMARK 1 AUTH J.RAAF,K.KLOPFFLEISCH,O.G.ISSINGER,K.NIEFIND REMARK 1 TITL THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 REMARK 1 TITL 2 STRUCTURALLY DEVIATES FROM ITS MAIZE HOMOLOGUE IN COMPLEX REMARK 1 TITL 3 WITH THE NUCLEOTIDE COMPETITIVE INHIBITOR EMODIN. REMARK 1 REF J.MOL.BIOL. V. 377 1 2008 REMARK 1 REFN ISSN 0022-2836 REMARK 1 PMID 18242640 REMARK 1 DOI 10.1016/J.JMB.2008.01.008 REMARK 1 REFERENCE 3 REMARK 1 AUTH K.NIEFIND,J.RAAF,O.G.ISSINGER REMARK 1 TITL PROTEIN KINASE CK2 IN HEALTH AND DISEASE: PROTEIN KINASE REMARK 1 TITL 2 CK2: FROM STRUCTURES TO INSIGHTS. REMARK 1 REF CELL.MOL.LIFE SCI. V. 66 1800 2009 REMARK 1 REFN ISSN 1420-682X REMARK 1 PMID 19387553 REMARK 1 DOI 10.1007/S00018-009-9149-8 REMARK 2 REMARK 2 RESOLUTION. 2.33 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX (PHENIX.REFINE: 1.7.3_928) REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : ML REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.33 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 31.81 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.350 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.9 REMARK 3 NUMBER OF REFLECTIONS : 15868 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.202 REMARK 3 R VALUE (WORKING SET) : 0.199 REMARK 3 FREE R VALUE : 0.249 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.820 REMARK 3 FREE R VALUE TEST SET COUNT : 924 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 31.8097 - 4.4537 1.00 2298 134 0.1822 0.2171 REMARK 3 2 4.4537 - 3.5365 1.00 2168 125 0.1594 0.1970 REMARK 3 3 3.5365 - 3.0899 1.00 2104 152 0.1957 0.2532 REMARK 3 4 3.0899 - 2.8076 1.00 2115 142 0.2177 0.2757 REMARK 3 5 2.8076 - 2.6065 1.00 2095 120 0.2309 0.2899 REMARK 3 6 2.6065 - 2.4529 1.00 2071 141 0.2604 0.3236 REMARK 3 7 2.4529 - 2.3300 1.00 2093 110 0.2775 0.3734 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : FLAT BULK SOLVENT MODEL REMARK 3 SOLVENT RADIUS : 1.20 REMARK 3 SHRINKAGE RADIUS : 0.98 REMARK 3 K_SOL : 0.36 REMARK 3 B_SOL : 36.04 REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.370 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 23.790 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 38.80 REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.03490 REMARK 3 B22 (A**2) : -0.03490 REMARK 3 B33 (A**2) : 0.06980 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.003 2905 REMARK 3 ANGLE : 0.677 3930 REMARK 3 CHIRALITY : 0.054 405 REMARK 3 PLANARITY : 0.003 505 REMARK 3 DIHEDRAL : 13.760 1098 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 2 REMARK 3 TLS GROUP : 1 REMARK 3 SELECTION: CHAIN A AND (RESSEQ 2:129) REMARK 3 ORIGIN FOR THE GROUP (A): 21.4813 -2.4221 28.1565 REMARK 3 T TENSOR REMARK 3 T11: 0.2637 T22: 0.2229 REMARK 3 T33: 0.1909 T12: 0.0886 REMARK 3 T13: -0.0320 T23: -0.0309 REMARK 3 L TENSOR REMARK 3 L11: 0.5073 L22: 0.5489 REMARK 3 L33: 1.1551 L12: -0.1326 REMARK 3 L13: -0.4666 L23: 0.2042 REMARK 3 S TENSOR REMARK 3 S11: 0.0063 S12: -0.0496 S13: -0.0297 REMARK 3 S21: 0.1075 S22: -0.0083 S23: -0.1731 REMARK 3 S31: 0.3167 S32: 0.0288 S33: 0.0000 REMARK 3 TLS GROUP : 2 REMARK 3 SELECTION: CHAIN A AND (RESSEQ 130:334) REMARK 3 ORIGIN FOR THE GROUP (A): 9.9097 16.2666 22.6869 REMARK 3 T TENSOR REMARK 3 T11: 0.0263 T22: 0.1690 REMARK 3 T33: 0.1777 T12: 0.0241 REMARK 3 T13: -0.0203 T23: 0.0169 REMARK 3 L TENSOR REMARK 3 L11: 1.4434 L22: 0.7826 REMARK 3 L33: 1.4880 L12: -0.0124 REMARK 3 L13: -0.3121 L23: -0.6591 REMARK 3 S TENSOR REMARK 3 S11: 0.0188 S12: 0.1931 S13: 0.2532 REMARK 3 S21: 0.1374 S22: 0.0246 S23: -0.0625 REMARK 3 S31: -0.0232 S32: -0.1307 S33: 0.0207 REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 4FBX COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 07-JUN-12. REMARK 100 THE DEPOSITION ID IS D_1000072708. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 14-DEC-10 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : SEALED TUBE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : OTHER REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : AGILENT ATLAS CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 15925 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.330 REMARK 200 RESOLUTION RANGE LOW (A) : 32.250 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.9 REMARK 200 DATA REDUNDANCY : 8.000 REMARK 200 R MERGE (I) : 0.09500 REMARK 200 R SYM (I) : 0.09500 REMARK 200 FOR THE DATA SET : 18.8000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : NULL REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : NULL REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHENIX REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 42.98 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.16 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: THE CONCENTRATED ENZYME SOLUTION REMARK 280 CONTAINED 6.2 MG/ML PROTEIN DISSOLVED IN 500 MM NACL, 25 MM TRIS/ REMARK 280 HCL, PH 8.5. NINE VOLUME PARTS OF THIS PROTEIN STOCK SOLUTION REMARK 280 WERE MIXED WITH ONE PART 12 MM ARC-1154 DISSOLVED IN 100% REMARK 280 DIMETHYL SULFOXIDE. THE CK2ALPHA1-335/ARC-1154 MIXTURE WAS REMARK 280 INCUBATED FOR 30 MIN AT ROOM TEMPERATURE. THE BEST CRYSTALS GREW REMARK 280 WITH A RESERVOIR SOLUTION COMPOSED OF 4.4 M NACL, 100 MM CITRIC REMARK 280 ACID, PH 5.25 AND MIXING 2 MICROLITER OF THIS RESERVOIR SOLUTION REMARK 280 WITH MICROLITER CK2ALPHA1-335/ARC-1154 MIXTURE, VAPOR DIFFUSION, REMARK 280 SITTING DROP, TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 43 21 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z+1/2 REMARK 290 3555 -Y+1/2,X+1/2,Z+3/4 REMARK 290 4555 Y+1/2,-X+1/2,Z+1/4 REMARK 290 5555 -X+1/2,Y+1/2,-Z+3/4 REMARK 290 6555 X+1/2,-Y+1/2,-Z+1/4 REMARK 290 7555 Y,X,-Z REMARK 290 8555 -Y,-X,-Z+1/2 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 67.52800 REMARK 290 SMTRY1 3 0.000000 -1.000000 0.000000 36.05700 REMARK 290 SMTRY2 3 1.000000 0.000000 0.000000 36.05700 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 101.29200 REMARK 290 SMTRY1 4 0.000000 1.000000 0.000000 36.05700 REMARK 290 SMTRY2 4 -1.000000 0.000000 0.000000 36.05700 REMARK 290 SMTRY3 4 0.000000 0.000000 1.000000 33.76400 REMARK 290 SMTRY1 5 -1.000000 0.000000 0.000000 36.05700 REMARK 290 SMTRY2 5 0.000000 1.000000 0.000000 36.05700 REMARK 290 SMTRY3 5 0.000000 0.000000 -1.000000 101.29200 REMARK 290 SMTRY1 6 1.000000 0.000000 0.000000 36.05700 REMARK 290 SMTRY2 6 0.000000 -1.000000 0.000000 36.05700 REMARK 290 SMTRY3 6 0.000000 0.000000 -1.000000 33.76400 REMARK 290 SMTRY1 7 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY2 7 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 8 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY2 8 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 67.52800 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 CHAIN B IS A BISUBSTRATE INHIBITOR, I.E. A MODIFIED CK2 SUBSTRATE REMARK 400 PEPTIDE TO WHICH AN ATP-COMPETITIVE INHIBITOR MOIETY IS LINKED. REMARK 400 ONLY THE LATTER IS DEFINED IN THE ELECTRON DENSITY WHILE THE REMARK 400 PEPTIDIC PART IS COMPLETELY FLEXIBLE PROBABLY DUE TO ITS HIGH REMARK 400 NEGATIVE CHARGE DENSITY. REMARK 400 REMARK 400 THE BISUBSTRATE INHIBITOR IS POLYPEPTIDE, A MEMBER OF ENZYME REMARK 400 INHIBITOR CLASS. REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: BISUBSTRATE INHIBITOR REMARK 400 CHAIN: B REMARK 400 COMPONENT_1: PEPTIDE LIKE POLYMER REMARK 400 DESCRIPTION: NULL REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 1 REMARK 465 GLY A 335 REMARK 465 GLY B 2 REMARK 465 ASP B 3 REMARK 465 ASP B 4 REMARK 465 ASP B 5 REMARK 465 ASP B 6 REMARK 465 ASP B 7 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 0TJ B 1 C1 C2 C3 C4 C5 C6 O1 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LEU A 45 -60.12 -109.98 REMARK 500 PRO A 72 90.89 -59.24 REMARK 500 VAL A 105 -61.54 -105.13 REMARK 500 TYR A 125 25.25 -74.21 REMARK 500 ASP A 156 42.70 -149.80 REMARK 500 ASP A 175 77.11 56.83 REMARK 500 ALA A 193 163.74 61.23 REMARK 500 ASP A 210 -154.41 -153.54 REMARK 500 HIS A 234 65.87 -103.23 REMARK 500 ASN A 289 -9.36 -144.17 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CL A 401 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CL A 402 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CL A 403 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CL A 404 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CL A 405 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN B OF BISUBSTRATE REMARK 800 INHIBITOR REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 3BQC RELATED DB: PDB REMARK 900 THE SAME PROTEIN IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR REMARK 900 EMODIN REMARK 900 RELATED ID: 1JWH RELATED DB: PDB REMARK 900 THE SAME PROTEIN INTEGRATED WITHIN THE HETEROTETRAMERIC CK2 REMARK 900 HOLOENZYME REMARK 900 RELATED ID: 3NSZ RELATED DB: PDB REMARK 900 THE SAME PROTEIN IN COMPLEX WITH AN ADP-ANALOGUE REMARK 900 RELATED ID: 3OFM RELATED DB: PDB REMARK 900 PARALOG ISOFORM OF HUMAN CK2ALPHA IN COMPLEX WITH AN ATP- REMARK 900 COMPETITIVE INHIBITOR REMARK 900 RELATED ID: 1LP4 RELATED DB: PDB REMARK 900 ORTHOLOG ENZYME FORM MAIZE IN COMPLEX WITH AN ATP-ANALOGUE AND TWO REMARK 900 MAGNESIUM IONS DBREF 4FBX A 1 335 UNP P68400 CSK21_HUMAN 1 335 DBREF 4FBX B 1 7 PDB 4FBX 4FBX 1 7 SEQRES 1 A 335 MET SER GLY PRO VAL PRO SER ARG ALA ARG VAL TYR THR SEQRES 2 A 335 ASP VAL ASN THR HIS ARG PRO ARG GLU TYR TRP ASP TYR SEQRES 3 A 335 GLU SER HIS VAL VAL GLU TRP GLY ASN GLN ASP ASP TYR SEQRES 4 A 335 GLN LEU VAL ARG LYS LEU GLY ARG GLY LYS TYR SER GLU SEQRES 5 A 335 VAL PHE GLU ALA ILE ASN ILE THR ASN ASN GLU LYS VAL SEQRES 6 A 335 VAL VAL LYS ILE LEU LYS PRO VAL LYS LYS LYS LYS ILE SEQRES 7 A 335 LYS ARG GLU ILE LYS ILE LEU GLU ASN LEU ARG GLY GLY SEQRES 8 A 335 PRO ASN ILE ILE THR LEU ALA ASP ILE VAL LYS ASP PRO SEQRES 9 A 335 VAL SER ARG THR PRO ALA LEU VAL PHE GLU HIS VAL ASN SEQRES 10 A 335 ASN THR ASP PHE LYS GLN LEU TYR GLN THR LEU THR ASP SEQRES 11 A 335 TYR ASP ILE ARG PHE TYR MET TYR GLU ILE LEU LYS ALA SEQRES 12 A 335 LEU ASP TYR CYS HIS SER MET GLY ILE MET HIS ARG ASP SEQRES 13 A 335 VAL LYS PRO HIS ASN VAL MET ILE ASP HIS GLU HIS ARG SEQRES 14 A 335 LYS LEU ARG LEU ILE ASP TRP GLY LEU ALA GLU PHE TYR SEQRES 15 A 335 HIS PRO GLY GLN GLU TYR ASN VAL ARG VAL ALA SER ARG SEQRES 16 A 335 TYR PHE LYS GLY PRO GLU LEU LEU VAL ASP TYR GLN MET SEQRES 17 A 335 TYR ASP TYR SER LEU ASP MET TRP SER LEU GLY CYS MET SEQRES 18 A 335 LEU ALA SER MET ILE PHE ARG LYS GLU PRO PHE PHE HIS SEQRES 19 A 335 GLY HIS ASP ASN TYR ASP GLN LEU VAL ARG ILE ALA LYS SEQRES 20 A 335 VAL LEU GLY THR GLU ASP LEU TYR ASP TYR ILE ASP LYS SEQRES 21 A 335 TYR ASN ILE GLU LEU ASP PRO ARG PHE ASN ASP ILE LEU SEQRES 22 A 335 GLY ARG HIS SER ARG LYS ARG TRP GLU ARG PHE VAL HIS SEQRES 23 A 335 SER GLU ASN GLN HIS LEU VAL SER PRO GLU ALA LEU ASP SEQRES 24 A 335 PHE LEU ASP LYS LEU LEU ARG TYR ASP HIS GLN SER ARG SEQRES 25 A 335 LEU THR ALA ARG GLU ALA MET GLU HIS PRO TYR PHE TYR SEQRES 26 A 335 THR VAL VAL LYS ASP GLN ALA ARG MET GLY SEQRES 1 B 7 0TJ GLY ASP ASP ASP ASP ASP HET 0TJ B 1 17 HET CL A 401 1 HET CL A 402 1 HET CL A 403 1 HET CL A 404 1 HET CL A 405 1 HETNAM 0TJ N-(6-OXOHEXYL)-2-(4,5,6,7-TETRABROMO-1H-BENZIMIDAZOL-1- HETNAM 2 0TJ YL)ACETAMIDE HETNAM CL CHLORIDE ION FORMUL 2 0TJ C15 H15 BR4 N3 O3 FORMUL 3 CL 5(CL 1-) FORMUL 8 HOH *122(H2 O) HELIX 1 1 ASP A 14 ARG A 19 1 6 HELIX 2 2 PRO A 20 ASP A 25 1 6 HELIX 3 3 ASN A 35 ASP A 37 5 3 HELIX 4 4 LYS A 74 ARG A 89 1 16 HELIX 5 5 THR A 129 MET A 150 1 22 HELIX 6 6 LYS A 158 HIS A 160 5 3 HELIX 7 7 SER A 194 LYS A 198 5 5 HELIX 8 8 GLY A 199 VAL A 204 1 6 HELIX 9 9 TYR A 211 ARG A 228 1 18 HELIX 10 10 ASP A 237 GLY A 250 1 14 HELIX 11 11 GLY A 250 TYR A 261 1 12 HELIX 12 12 ASP A 266 GLY A 274 1 9 HELIX 13 13 ARG A 280 VAL A 285 5 6 HELIX 14 14 ASN A 289 VAL A 293 5 5 HELIX 15 15 SER A 294 LEU A 305 1 12 HELIX 16 16 THR A 314 GLU A 320 1 7 HELIX 17 17 HIS A 321 TYR A 323 5 3 HELIX 18 18 PHE A 324 ALA A 332 1 9 SHEET 1 A 5 TYR A 39 ARG A 47 0 SHEET 2 A 5 SER A 51 ASN A 58 -1 O GLU A 55 N ARG A 43 SHEET 3 A 5 LYS A 64 LEU A 70 -1 O ILE A 69 N GLU A 52 SHEET 4 A 5 PRO A 109 GLU A 114 -1 O PHE A 113 N VAL A 66 SHEET 5 A 5 LEU A 97 LYS A 102 -1 N ALA A 98 O VAL A 112 SHEET 1 B 2 ILE A 152 MET A 153 0 SHEET 2 B 2 GLU A 180 PHE A 181 -1 O GLU A 180 N MET A 153 SHEET 1 C 2 VAL A 162 ASP A 165 0 SHEET 2 C 2 LYS A 170 LEU A 173 -1 O ARG A 172 N MET A 163 CISPEP 1 GLU A 230 PRO A 231 0 -4.39 SITE 1 AC1 2 HIS A 148 ALA A 315 SITE 1 AC2 3 ARG A 155 TYR A 188 ASN A 189 SITE 1 AC3 3 HOH A 566 HOH A 568 HOH A 586 SITE 1 AC4 3 LYS A 122 PRO A 159 HIS A 160 SITE 1 AC5 4 LYS A 229 PHE A 232 HIS A 234 ARG A 244 SITE 1 AC6 7 ILE A 95 VAL A 116 ASN A 118 HIS A 160 SITE 2 AC6 7 MET A 163 ILE A 174 HOH A 595 CRYST1 72.114 72.114 135.056 90.00 90.00 90.00 P 43 21 2 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.013867 0.000000 0.000000 0.00000 SCALE2 0.000000 0.013867 0.000000 0.00000 SCALE3 0.000000 0.000000 0.007404 0.00000